New two-year data show 39 percent patients treated with CAR T remain in remission

A new article shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta® (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive.

from Latest Science News -- ScienceDaily https://ift.tt/2RqYN4s
via IFTTT